(RTTNews) - Japan's Takeda Pharmaceutical Co. Ltd. (TAK) announced Tuesday that the Phase 3 SHP643-301 study (NCT04070326) evaluating the safety profile and pharmacokinetics (PK) of Takhzyro ...
(RTTNews) - Cytokinetics (CYTK) presented data from the Phase 1 study of CK-4021586, or CK-586. The study met its primary and secondary objectives to assess the safety, tolerability and ...
PepGen (PEPG) announced positive clinical data from the 15 mg/kg dose cohort of its ongoing FREEDOM-DM1 Phase 1 single ascending dose study in patients with myotonic dystrophy type 1. These latest ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback